From 2012.igem.org
(Difference between revisions)
|
|
| Line 5: |
Line 5: |
| | | | |
| | === Introduction === | | === Introduction === |
| - |
| |
| - | Modelling can be the final application, which could be modelling the VLP dose in case of drug delivery. A second possibility is predicting the folding of VLPs. It is known that the modification of a monomer influences the folding of the total VLP. Looking at the loops of the Hepatitis B VLP, this makes sense. These loops would be the primary target for modification, but are paired in the VLP structure. So, if the loops of both monomers are modified, it is very likely that the modification will interfere with the VLP formation.
| |
Revision as of 10:00, 25 May 2012
Modelling
Introduction
"
